Literature DB >> 8384406

Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas.

W Domagala1, B Harezga, A Szadowska, M Markiewski, K Weber, M Osborn.   

Abstract

Striking differences were found between different histological types of breast cancer when 263 invasive breast carcinomas were tested for nuclear p53 accumulation in formaldehyde-fixed paraffin sections. Nuclear p53 accumulation was found in > 10% of tumor cells in 61% of medullary carcinomas (22/36), 37% of grade 3 ductal not otherwise specified carcinomas (32/86), 4% of lobular carcinomas (2/47), and 0% (0/7) of mucinous carcinomas. Strong cytoplasmic p53 staining was noted in 32% of lobular carcinomas. High percentages of medullary and high-grade ductal breast carcinomas accumulate nuclear p53, but these tumors have favorable and poor prognoses, respectively. Thus, whereas nuclear p53 accumulation can be associated in these tumors with high morphological malignancy grades in general and with tumor cell proliferation in particular, p53 accumulation is not necessarily correlated with biological aggressiveness. Overall incidence of p53-positive tumors in a particular series of breast carcinomas (in our study 28%) will depend on the ratio of ductal not otherwise specified, medullary, and lobular carcinomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384406      PMCID: PMC1886797     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

1.  Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells.

Authors:  H W Stürzbecher; P Chumakov; W J Welch; J R Jenkins
Journal:  Oncogene       Date:  1987-05       Impact factor: 9.867

2.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

3.  Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; A Rejthar; J Kovarík; D P Lane
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

Review 4.  Prognosis and breast cancer. Recognition of lethal and favorable prognostic types.

Authors:  D L Page
Journal:  Am J Surg Pathol       Date:  1991-04       Impact factor: 6.394

5.  Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas.

Authors:  W Domagala; L Woźniak; J Lasota; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

6.  P53 expression in breast cancer.

Authors:  G Cattoretti; F Rilke; S Andreola; L D'Amato; D Delia
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

7.  The cellular protein p53 in human tumours.

Authors:  L V Crawford; D C Pim; P Lamb
Journal:  Mol Biol Med       Date:  1984-08

8.  Localization of the E1B proteins of adenovirus 5 in transformed cells, as revealed by interaction with monoclonal antibodies.

Authors:  A Zantema; J A Fransen; A Davis-Olivier; F C Ramaekers; G P Vooijs; B DeLeys; A J Van der Eb
Journal:  Virology       Date:  1985-04-15       Impact factor: 3.616

9.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

Authors:  J V Gannon; R Greaves; R Iggo; D P Lane
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

10.  Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas.

Authors:  G Cattoretti; S Andreola; C Clemente; L D'Amato; F Rilke
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640

View more
  14 in total

1.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

2.  Expression of p53 oncoprotein in different histological types of breast carcinoma.

Authors:  M Martinazzi
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

3.  Prognostic markers for colorectal cancer: expression of P53 and BCL2.

Authors:  H Pereira; S Silva; R Julião; P Garcia; F Perpétua
Journal:  World J Surg       Date:  1997-02       Impact factor: 3.352

4.  Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study.

Authors:  I F O'Connor; M V Shembekar; S Shousha
Journal:  J Clin Pathol       Date:  1998-12       Impact factor: 3.411

5.  Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive.

Authors:  W Domagala; M Markiewski; R Kubiak; J Bartkowiak; M Osborn
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases.

Authors:  G MacGrogan; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

7.  Nuclear image analysis of immunohistochemically stained cells in breast carcinomas.

Authors:  G Haroske; V Dimmer; K Friedrich; W Meyer; B Thieme; F Theissig; K D Kunze
Journal:  Histochem Cell Biol       Date:  1996-06       Impact factor: 4.304

8.  H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression.

Authors:  E Adriaenssens; L Dumont; S Lottin; D Bolle; A Leprêtre; A Delobelle; F Bouali; T Dugimont; J Coll; J J Curgy
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

9.  Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction.

Authors:  W Gorczyca; M Markiewski; A Kram; T Tuziak; W Domagala
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  p53 as a prognostic factor in stage I breast cancer. South-East Sweden Breast Cancer Group.

Authors:  M Stenmark-Askmalm; O Stål; K Olsen; B Nordenskjöld
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.